{"id":"W4318773806","doi":"10.1136/jitc-2022-006127","title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"EMD Serono; Ipsen; Universiteit Gent; Astellas Pharma; Eisai; G1 Therapeutics; Sanofi; Apollomics; Agios Pharmaceuticals; University of Texas Southwestern Medical Center; BeiGene; GlaxoSmithKline; Tizona Therapeutics; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; AstraZeneca; Novocure; MacroGenics; Celldex Therapeutics; Cilag; Puma Biotechnology; Regeneron Pharmaceuticals; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Celgene; PTC Therapeutics; Genentech; Aeglea BioTherapeutics; Amgen; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Internal medicine; Lung cancer; Metastatic melanoma; First line; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009502174,0.0003372715,0.0006811331,0.0002594779,0.0003113757,0.0004620058,0.0003620464,0.0002968478,0.0015541],"category_scores_gemma":[0.0005261944,0.0001238491,0.0007526248,0.0002447596,0.0001690836,0.0002509831,0.000247322,0.0007458538,0.0002325735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006493707,"about_ca_system_score_gemma":0.001030166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001106575,"about_ca_topic_score_gemma":0.007094131,"domain_scores_codex":[0.9997752,0.00007650402,0.00001667837,0.00005278402,0.00004215004,0.00003661431],"domain_scores_gemma":[0.9995504,0.00008242142,0.0001033666,0.00003893661,0.00005016505,0.0001747151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1310634,0.01841961,0.3762323,0.002308731,0.003945272,0.0007785278,0.0003924324,0.004338611,0.05091593,0.0003316717,0.008404273,0.4028692],"study_design_scores_gemma":[0.0485104,0.262398,0.6511623,0.0002311016,0.002923847,0.002246409,0.0001668992,0.003927083,0.01250147,0.0002456197,0.01563978,0.00004709499],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949898,0.002835805,0.0001518423,0.00009228673,0.0000251881,0.0003065859,0.0004958478,0.00001602486,0.001086603],"genre_scores_gemma":[0.9957349,0.001104975,0.0004681331,0.0002561817,0.00004838729,0.0001745653,0.00167071,0.000004526546,0.0005374786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0015541,"threshold_uncertainty_score":0.005199015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04147329883353722,"score_gpt":0.3365720828331165,"score_spread":0.2950987839995792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}